Meliodays Medical announces the closing of a pre-seed financing round of over EUR 800,000
|
EQS-News: meliodays medical GmbH
/ Key word(s): Financing
Meliodays Medical announces the closing of a pre-seed financing round of over EUR 800,000
Munich, March 20, 2025 – Meliodays Medical GmbH, a young pharmaceutical company focusing on the development of a new therapy for hormone-free, local treatment of menstrual pain, today announces the successful completion of an oversubscribed pre-seed financing round of over EUR 800,000 led by capacura GmbH with participation from FS Life Science Investment GmbH and other early-stage investors and business angels specializing in the healthcare market. Simone Sabbione, co-founder and CEO of Meliodays Medical, explained: ‘We are delighted to have attracted such experienced healthcare and impact investors for our first financing round and warmly welcome them to the Meliodays shareholder group. Their investment and the strong interest in our significantly oversubscribed pre-seed round show that period pain is now recognized as a significant health burden affecting large portions of the global population. Now, we can finally work on urgently needed innovative solutions.’ About 80 percent of menstruating people experience period pain, with 20-30 percent finding it severe enough to limit their ability to attend school, work and social activities at times, often requiring the use of pain medication. However, currently available treatment options, such as hormone therapies or high-dose painkillers, are often associated with systemic side effects. Meliodays Medical will use the proceeds to advance the development of MelioOne, a novel, hormone-free, locally acting treatment for menstrual pain, and to complete preparations for the preclinical development of its innovative intrauterine application. Using a proven polymer technology, a very small amount of pain medication is released directly into the uterus, to effectively treat period pain while avoiding systemic side effects. In the future, Meliodays Medical’s innovative technology could also be used in the treatment of endometriosis The company has already secured patent rights for MelioOne in over 150 countries. About Meliodays Medical Meliodays Medical GmbH, is a young pharmaceutical company focused on developing a new therapy for hormone-free, local treatment of menstrual pain. Meliodays Medical is developing MelioOne, the first hormone-free, local solution to treat menstrual pain without systemic side effects, thus addressing an area of high unmet medical need. With its innovative healthcare solutions, Meliodays is paving the way to a better quality of life for menstruating people, enabling them to have a pain-free period without affecting their menstrual cycle. For further information, please visit www.meliodays.com and follow us on LinkedIn or Instagram.
20.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2103324 20.03.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.